KR20180102868A - Composition comprising Vegetable Oil for preventing, alleviating or treatment of congnitive dysfunction disorder - Google Patents
Composition comprising Vegetable Oil for preventing, alleviating or treatment of congnitive dysfunction disorder Download PDFInfo
- Publication number
- KR20180102868A KR20180102868A KR1020170029573A KR20170029573A KR20180102868A KR 20180102868 A KR20180102868 A KR 20180102868A KR 1020170029573 A KR1020170029573 A KR 1020170029573A KR 20170029573 A KR20170029573 A KR 20170029573A KR 20180102868 A KR20180102868 A KR 20180102868A
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- composition
- group
- color
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 235000015112 vegetable and seed oil Nutrition 0.000 title description 6
- 239000008158 vegetable oil Substances 0.000 title description 4
- 230000004064 dysfunction Effects 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims description 15
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 abstract description 20
- 230000003930 cognitive ability Effects 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 69
- 235000019198 oils Nutrition 0.000 description 68
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 20
- 239000003549 soybean oil Substances 0.000 description 19
- 235000012424 soybean oil Nutrition 0.000 description 19
- 235000004347 Perilla Nutrition 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 244000124853 Perilla frutescens Species 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 15
- 239000008157 edible vegetable oil Substances 0.000 description 14
- 229960003180 glutathione Drugs 0.000 description 14
- 102000012440 Acetylcholinesterase Human genes 0.000 description 13
- 108010022752 Acetylcholinesterase Proteins 0.000 description 13
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 229940118019 malondialdehyde Drugs 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229940022698 acetylcholinesterase Drugs 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 240000004160 Capsicum annuum Species 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 10
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 10
- 235000013734 beta-carotene Nutrition 0.000 description 10
- 239000011648 beta-carotene Substances 0.000 description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 10
- 229960002747 betacarotene Drugs 0.000 description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 235000012661 lycopene Nutrition 0.000 description 10
- 229960004999 lycopene Drugs 0.000 description 10
- 239000001751 lycopene Substances 0.000 description 10
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 10
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 9
- 229960004373 acetylcholine Drugs 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108010024636 Glutathione Proteins 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012347 Morris Water Maze Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- -1 olive oil Chemical compound 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000001511 capsicum annuum Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000013016 learning Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 108010053070 Glutathione Disulfide Proteins 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 5
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000006886 spatial memory Effects 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000019482 Palm oil Nutrition 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002540 palm oil Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 241000167854 Bourreria succulenta Species 0.000 description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 3
- 235000007862 Capsicum baccatum Nutrition 0.000 description 3
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 3
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 3
- 240000008067 Cucumis sativus Species 0.000 description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 description 3
- 244000300264 Spinacia oleracea Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000001728 capsicum frutescens Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000019693 cherries Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000241235 Citrullus lanatus Species 0.000 description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 2
- 244000175448 Citrus madurensis Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 235000017317 Fortunella Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 244000062780 Petroselinum sativum Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000003484 annual ragweed Nutrition 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000006263 bur ragweed Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 235000003488 common ragweed Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 235000011197 perejil Nutrition 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000009736 ragweed Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- KWTSZCJMWHGPOS-UHFFFAOYSA-M chloro(trimethyl)stannane Chemical compound C[Sn](C)(C)Cl KWTSZCJMWHGPOS-UHFFFAOYSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000006103 coloring component Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000010461 other edible oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000010913 used oil Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 칼라 오일을 유효성분으로 포함하는 인지기능 장애 관련 질환의 예방, 완화 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, alleviating or treating a cognitive dysfunction-related disease comprising color oil as an active ingredient.
유지는 전통적으로 식물, 동물, 어류 등에서 얻으며, 특히 천연 유지는 지방산의 탄소수, 지방산의 포화정도, 이성질체의 함량, 지방의 다형성(polymorphic state)에 따라 다양한 물리적ㆍ화학적 성질을 가진다. 일반적으로 식용유지는 일반적으로 먹을 수 있는 기름(상온에서 액체)과 지방(상온에서 고체)의 총칭으로, 유지를 함유한 식물 또는 동물로부터 얻은 원유를 원료로 하여 제조 가공한 대두유, 옥수수기름, 채종유, 현미유, 참기름, 들기름, 홍화유, 해바라기유, 목화씨기름, 땅콩기름, 올리브유, 팜유, 야자유, 고추씨기름, 기타 식용유지 등을 말한다. Fat is traditionally obtained from plants, animals, fish, etc. In particular, natural fat has various physical and chemical properties depending on the number of carbon atoms in the fatty acid, the degree of saturation of the fatty acid, the content of the isomer, and the polymorphic state of the fat. In general, edible oil is a generic term for commonly used oil (liquid at normal temperature) and fat (solid at normal temperature), and is derived from soybean oil, corn oil, vegetable oil, Sesame oil, sesame oil, safflower oil, sunflower oil, cottonseed oil, peanut oil, olive oil, palm oil, palm oil, red pepper seed oil and other edible oils.
식물성 식용유지를 일반적으로 식용유라고 한다. 영양학적으로 유지는 1 g 당 9 kcal의 열량을 내는데 이 값은 단백질이나 탄수화물에 비하여 두 배에 가까운 수치이다. 서구의 경우에는 섭취 에너지의 35~40% 정도를 유지를 통해서 얻고 있는데, 이러한 지방의 과다섭취는 심장질환, 비만과 암의 유발 등 건강상의 문제점을 일으키는 바, 이에 대한 사람들의 관심이 높이지고 있다.Vegetable oil is generally called edible oil. Nutritionally, the calorie consumes 9 calories per gram, which is nearly double that of protein or carbohydrates. In Western countries, 35 to 40% of the energy intake is maintained through maintenance. Excessive intake of such fat causes health problems such as heart disease, obesity and cancer, and people's interest is increasing .
최근 사회의 경제적 여유가 생기면서 소비자들의 건강 및 미감에 대한 관심이 높아지고 있는바, 종래의 액상 식용유지에 각종 기능성 첨가물을 추가하여 건강에도 좋고 시각적으로도 아름다운 유지를 찾는 소비자의 요구에 따라 다양한 시도가 계속되고 있다. 이때 첨가물에 의해 식용유지 고유의 풍미가 저하되지 않도록 하는 것이 중요하다. In recent years, interest in health and aesthetics of consumers has been increasing due to the economical margin of society. As a result, various functional additives are added to the conventional liquid edible oil to make various attempts according to consumers' Is continuing. At this time, it is important that the flavor inherent to the edible oil is not lowered by the additive.
한편, 뇌(brain)와 척수 (spinal cord)로 구성된 중추신경계는 생명현상을 운영하는 중심센터로서 감각과 (불)수의적인 운동에서부터 사고, 기억, 감정, 언어 등에 이르기까지 인체의 모든 기능을 총괄하는 아주 필수적인 기관이다. 따라서 뇌졸중, 외상 등으로 야기된 급행적인 신경세포의 사멸이나, 알츠하이머병으로 대표되는 노인성 치매, 파킨슨질환 등과 같은 중추신경계 퇴행성 질환을 유발시키는 서행적인 신경세포의 사멸등과 같은 모든 경우에서는 곧 바로 신경회로망의 비가역적인 기능장애를 초래하게 되며 결국에는 해당 인체 기능의 영구적인 손실을 초래하게 된다. The central nervous system, which consists of the brain and spinal cord, is a central center for the management of life phenomena. It is responsible for all functions of the human body, from sensory and (voluntary) exercises to thinking, memory, Is a very essential institution. Therefore, in all cases, such as the death of rapid nerve cells caused by stroke or trauma, or the death of slow nerve cells that cause degenerative diseases of the central nervous system such as senile dementia represented by Alzheimer's disease and Parkinson's disease, Resulting in an irreversible dysfunction of the network and eventually a permanent loss of the corresponding human function.
알츠하이머병으로 대표되는 노인성 치매는 인간 평균수명의 연장과 의료복지시설의 현대화와 맞물려 비례적으로 증가하는 특성을 가지고 있다. 보건사회연구원 통계조사에 다르면 우리나라의 노인인구가 2000년에 7%를 넘어 고령사회에 진입한 이래 2003년 397만 명으로 노인인구의 비율이 8.3%에 이르렀고 2019년에는 14.4%에 이르러 완전고령사회에 진입할 것으로 예견된다. 65세 이상 노인인구 중 한 가지 이상 만성질환을 가지고 있는 노인은 에 이르며 특히 65세 이상 노인의 치매 유병율도 8.2%로 추정된다. 서구사회에서는 65세 이상인구의 약 10%, 80세 이상인구의 약 40 ~ 50%에서 알츠하이머병이 발생하고 있으며, 이미 미국에서는 이 질환환자가 500만 명 이상으로 이로 인한 의료비 지출이 연간 1000억 달러로 추정되고 있다. 또한 우리나라에서는 약 20만 명 이상이 치매 환자인 것으로 나타났다. 미국의 경우 2030년까지 현재의 2배 규모로 증가하고, 2050년까지는 350% 이상 늘어난 1,400만 명에 달할 것으로 추정되어지고 있다.Elderly dementia, represented by Alzheimer 's disease, is characterized by an increase in the life expectancy of the human being and a proportional increase in association with the modernization of medical welfare facilities. According to the statistics of the Korea Institute for Health and Social Affairs, the elderly population of Korea exceeded 7% in 2000 and entered the aged society. In 2003, the number of elderly people reached 8.3%, 3.97% in 2003 and 14.4% . The prevalence of dementia in elderly people over 65 years of age is estimated to be 8.2%. In the western world, approximately 10% of the population aged 65 and over, 40-50% of the population aged 80 or older are developing Alzheimer's disease, and the US already has over 5 million people with this disease, It is estimated to be in dollars. In Korea, more than 200,000 people were found to be dementia patients. In the United States, it is estimated that it will double to 2030 by 2030 and reach more than 14 million by 2050 by more than 350%.
이에 본 발명자는 천연 소재로부터 유래한 천연 색소의 함유량을 높이고 이를 이용하여 아름다운 색택을 나타내며, 기능성과 관능성이 뛰어난 칼라 오일을 제조하고자 예의 노력한 결과, 본 발명의 칼라오일을 완성하였으며, 상기 칼라오일이 인지기능 장애의 예방, 완화 또는 치료 용도를 가짐을 확인하고 본 발명을 완성하였다. Accordingly, the present inventors have made intensive efforts to produce a color oil having a high content of natural pigments derived from natural materials and exhibiting a beautiful coloring property using the same, and having excellent functionality and functionality. As a result, the color oil of the present invention was completed. And has the purpose of preventing, alleviating or treating the cognitive dysfunction, and the present invention has been completed.
본 발명의 목적은 칼라 오일을 유효성분으로 포함하는 인지기능 장애 관련 질환의 예방, 완화 또는 치료용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for preventing, alleviating or treating cognitive dysfunction-related diseases comprising color oil as an active ingredient.
상기 과제를 해결하기 위하여, 본 발명은 칼라 오일을 유효성분으로 포함하는 인지기능 장애 관련 질환의 예방, 완화 또는 치료용 약학적 조성물을 제공한다.In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing, alleviating or treating cognitive dysfunction-related diseases comprising color oil as an active ingredient.
또한, 본 발명은 칼라 오일을 유효성분으로 포함하는 인지기능 장애 관련 질환의 예방 또는 완화용 건강기능식품 조성물을 제공한다.Further, the present invention provides a health functional food composition for preventing or alleviating cognitive dysfunction-related diseases comprising color oil as an active ingredient.
생체 적합성이 높은 천연 물질을 이용하여 제조한 본 발명에 의한 칼라 오일은 심미적으로도 아름다우면서 인지 능력을 효율적으로 개선시키는 바, 인지기능 장내 관련 질환의 치료제, 건강기능식품 등 다양한 물질로 활용될 수 있다. The color oil according to the present invention, which is manufactured using natural materials having high biocompatibility, is aesthetically beautiful and improves the cognitive ability efficiently, and can be utilized as various substances such as therapeutic agents for cognitive function disorders, health functional foods and the like .
도 1은 본 발명의 칼라 오일의 외관을 나타내는 도이다.
도 2는 Y-미로 실험을 통한 칼라 오일의 인지능력 개선 효과를 확인한 결과를 나타내는 도이다.
도 3은 모리스 수중 미로 실험을 통한 칼라 오일의 기억력 및 학습능력 개선 효과를 확인한 결과를 나타내는 도이다.
도 4는 아세틸콜린 에스터라제(AChE) 및 말론디알데히드(MDA)의 함량 변화 관찰을 통한 칼라 오일의 신결 전달 능력 및 지질 과산화 억제 활성을 확인한 결과를 나타내는 도이다.
도 5는 과산화물제거효소(SOD) 및 글루타티온(GSH) 함량 변화를 통한 칼라 오일의 항산화 효과를 확인한 결과를 나타내는 도이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a view showing the appearance of a color oil of the present invention. FIG.
Fig. 2 is a graph showing the results of confirming the effect of improving the cognitive ability of color oil through the Y-maze experiment.
FIG. 3 is a diagram showing the results of confirming the effect of improving the memory ability and learning ability of color oil through the Morris water maze test.
FIG. 4 is a graph showing the results of confirming the activity of inhibiting the development of color oil and inhibiting lipid peroxidation through observation of changes in the content of acetylcholine esterase (AChE) and malondialdehyde (MDA).
FIG. 5 is a graph showing the results of confirming the antioxidative effect of color oil through changes in peroxide elimination enzyme (SOD) and glutathione (GSH) contents.
본 발명은 칼라 오일을 유효성분으로 포함하는 인지기능 장애 관련 질환의 예방, 완화 또는 치료용 조성물을 제공한다.The present invention provides a composition for preventing, alleviating or treating cognitive dysfunction-related diseases comprising color oil as an active ingredient.
이하 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 있어서, '칼라 오일'은 본 발명자들이 새롭게 제조한 유지로, 바람직하게는 칼라 오일 100g에 대해 라이코펜을 50 내지 1500 μg, 베타카로틴을 50 내지 150 μg을 포함하는 것이다. 상기 칼라 오일은 잔유물 없이 투명하고 아름다운 색택을 나타내며, 라이코펜 또는 베나카로틴을 높게 함유하고, 산패 방지 및 항산화능 등 기능성을 가지고 있으며, 관능성이 뛰어난 효과가 있다.In the present invention, 'color oil' is a fat-oil produced by the present inventors, preferably 50 to 1500 μg of lycopene and 50 to 150 μg of beta-carotene per 100 g of color oil. The color oil exhibits a clear and beautiful colorless state without residue, has a high content of lycopene or benacarotin, has functionality such as antioxidant and antioxidant ability, and has an excellent effect.
본 발명에 있어서, 상기 칼라 오일은 인지능력 개선 및 기억력 개선 효과가 우수하므로, 인지기능 장애의 예방 또는 치료에 유용하게 사용될 수 있다.In the present invention, the color oil is excellent in improving cognitive ability and memory effect, and thus can be effectively used for preventing or treating cognitive dysfunction.
상기 인지기능 장애 관련 질환은 알츠하이머병(Alzheimer's disease), 혈관성 치매(Vascular dementia), 루이 소체 치매(Diffuse lewy body dementia), 헌팅톤병(Huntington's disease), 픽(pick)병, 크루츠펠트-야곱(Creutzfeldt-jakob)병, 두부손상에 의한 치매 또는 파킨슨병(Parkinson's disease) 등을 포함하나, 이에 한정되는 것은 아니다.The cognitive dysfunction-related diseases are selected from the group consisting of Alzheimer's disease, vascular dementia, Diffuse lewy body dementia, Huntington's disease, pick disease, Kruszfeld- Creutzfeldt-Jakob disease, dementia due to head injury, or Parkinson ' s disease.
본 발명에 있어서, 상기 조성물은 칼라 오일과 함께 인지기능 장애에 대하여 예방 또는 치료의 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다. In the present invention, the composition may contain, in addition to color oil, at least one known active ingredient having an effect of preventing or treating cognitive dysfunction.
상기 조성물은 약학적 조성물 및 식품 조성물을 포함한다. 특히, 식품 조성물 중에서도 건강기능식품을 포함한다.The composition comprises a pharmaceutical composition and a food composition. Particularly, it includes health functional foods among food compositions.
본 발명에 있어서, 상기 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 또한, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 당해 기술 분야에 알려진 적합한 제제는 문헌 (Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 사용하는 것이 바람직하다. 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등이 있다. 상기 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로오스, 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. In the present invention, the composition may further comprise suitable carriers, excipients and diluents conventionally used in the production of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral formulations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.
본 발명의 약학적 조성물의 바람직한 투여량은 개체의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 바람직한 효과를 위해서, 본 발명의 개똥쑥 추출물은 1일 0.1 mg/ kg 내지 50000 mg/kg의 양으로 투여할 수 있으며, 하루에 한 번 투여할 수도 있고, 수 회 나누어 투여할 수도 있다. The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the individual, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For the desired effect, the rabbit extract of the present invention may be administered in an amount of 0.1 mg / kg to 50000 mg / kg per day, and may be administered once a day or divided into several times.
본 발명의 약학적 조성물은 이를 필요로 하는 개체에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention can be administered to a subject in need thereof by various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명의 조성물은 인지기능 장애의 예방 및 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention and treatment of cognitive dysfunction.
본 발명에서, "건강기능식품"이란, 질병의 예방 및 개선, 생체방어, 면역, 병후의 회복, 노화 억제 등 생체조절 기능을 가지는 식품을 말하는 것으로, 장기적으로 복용하였을 때 인체에 무해해야 한다. In the present invention, the term "health functional food" refers to a food having a biological control function such as prevention and improvement of disease, bio-defense, immunity, recovery after disease and aging inhibition.
본 발명의 조성물은 인지기능 장애의 예방 또는 개선을 목적으로 건강기능식품에 첨가될 수 있다. 본 발명의 개똥쑥 추출물을 식품 첨가물로 사용할 경우, 상기 개똥쑥 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 본 발명의 개똥쑥 추출물은 원료에 대하여 15중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The composition of the present invention may be added to a health functional food for the purpose of preventing or improving cognitive dysfunction. When the rabbit extract of the present invention is used as a food additive, the ragweed extract can be used as it is or can be used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the ragweed extract of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, when the food or beverage is produced. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 포함할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토오스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml 당 일반적으로 약 0.01 내지 10 g, 바람직하게는 약 0.01 내지 0.1 g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
또한, 본 발명은 또 다른 양태로 (a) 라이코펜 또는 베타카로틴을 함유하는 소재로부터 정유 물질을 추출하는 단계; 및 (b) 상기 (a)단계에서 수득한 정유물질을 식용유지와 혼합, 교반하는 단계;를 포함하는 천연 색소를 포함하는 칼라 오일의 제조방법을 제공한다. The present invention also provides, in yet another aspect, (a) a process for extracting an essential oil from a material containing lycopene or beta-carotene; And (b) mixing and stirring the essential oil obtained in step (a) with an edible oil, and stirring the oil.
상기 (a)단계에서 소재는 라이코펜 또는 베타카로틴을 함유하고 있는 채소 또는 과일이면 어떤 것이든 이용될 수 있으며, 이에 제한되지 않으나, 그 예로 파프리카, 토마토, 앵두, 고추, 오미자, 수박, 당근, 감, 오렌지, 귤, 금귤, 호박, 노란색 대추방울토마토, 피망, 풋고추, 미나리, 오이, 상추, 시금치, 브로콜리, 매실로 이루어진 군에서 선택된 하나 이상일 수 있다. In step (a), the material may be any of vegetables or fruits containing lycopene or beta-carotene. Examples of such materials include, but are not limited to, paprika, tomato, cherry, red pepper, Green pepper, green pepper, parsley, cucumber, lettuce, spinach, broccoli, and plum.
상기 (a) 단계에서 추출되는 정유 물질은 라이코펜 또는 베타카로틴일 수 있다. The refining substance extracted in the step (a) may be lycopene or beta-carotene.
상기 (a) 단계에서 고효율로 라이코펜 또는 베타카로틴을 수득하기 위하여 초임계 유체 추출을 이용할 수 있으며, 초임계 유체는 이산화탄소가 바람직하다. 초임계 유체 추출 시, 이산화탄소를 단독으로 사용하거나, 유기용매를 보조 용매로 혼합하여 사용할 수 있다. 상기 유기용매의 종류는 이에 제한되지 않으나 바람직하게는 에탄올이고, 보다 바람직하게는 95% 이상의 에탄올이다. 상기 유기용매의 농도가 95% 미만일 경우, 추출물을 농축한 후 추출물에 수분함량이 상대적으로 높아져 식용유지에 첨가 시 수분함량이 높아지는 문제점이 있으며, 변색, 침전 등 제품의 안정성이 저하될 우려가 있다. 상기 이산화탄소와 유기용매의 혼합 비율은 10:1 내지 2:1 일 수 있다. In step (a), supercritical fluid extraction may be used to obtain lycopene or beta-carotene with high efficiency, and carbon dioxide is preferably used as the supercritical fluid. When supercritical fluid is extracted, carbon dioxide may be used alone, or an organic solvent may be mixed with an auxiliary solvent. The kind of the organic solvent is not limited thereto, but is preferably ethanol, more preferably at least 95% ethanol. If the concentration of the organic solvent is less than 95%, there is a problem that the water content of the extract is relatively high after concentrating the extract, thereby increasing the water content when added to the edible oil, and there is a fear that the stability of the product such as discoloration and precipitation is lowered . The mixing ratio of the carbon dioxide to the organic solvent may be 10: 1 to 2: 1.
상기 (a) 단계는 온도 30 내지 60 ℃, 압력 100 내지 300 bar에서 이루어질 수 있어, 고온 추출에 따른 색소 성분의 파괴를 방지할 수 있다. 상기 (a) 단계의 정유물질의 추출 시간은 바람직하게는 1 내지 3시간이며, 보다 바람직하게는 2시간이다. 추출 시간이 1시간 미만이면 추출 효율이 현저히 떨어지고, 3시간 초과이면 추출 효율이 더 이상 증가하지 않는다. The step (a) may be performed at a temperature of 30 to 60 ° C and a pressure of 100 to 300 bar, thereby preventing the destruction of the coloring component due to high-temperature extraction. The extraction time of the refinery material in step (a) is preferably 1 to 3 hours, more preferably 2 hours. If the extraction time is less than 1 hour, the extraction efficiency is significantly lowered. If the extraction time exceeds 3 hours, the extraction efficiency is not increased any more.
상기 (b) 단계에서 식용유지는 이에 제한되지는 않으나, 대두유, 옥수수유, 유채유, 채종유, 현미유, 해바라기유, 올리브유, 야자유, 팜유, 홍화씨기름, 참기름, 들기름, 땅콩기름 및 고추씨기름으로 이루어진 군으로부터 선택된 하나 이상일 수 있다. 상기 식용유지는 갈변이 되지 않으며, 유지 자체의 채도가 높지 않아 본 발명의 칼라 오일의 제조에 바람직하다. In the step (b), the edible oil is not limited to the group consisting of soybean oil, corn oil, rape seed oil, seed oil, sunflower oil, olive oil, palm oil, palm oil, safflower oil, sesame oil, perilla oil, peanut oil, It may be more than one selected. The edible oil is not browned, and the oiliness of the oil itself is not high, which is preferable for the production of the color oil of the present invention.
상기 (b) 단계에서 정유 물질은 식용유지 총 중량에 대해 1 내지 5 중량% 포함되는 것이 바람직하다. 정유물질의 함량이 1 중량% 미만이면 색택의 채도 및 특유의 향취가 떨어지고, 5 중량%를 초과하면 탁도가 높아지고, 침전물 발생우려가 있다. In the step (b), it is preferable that the refined material is contained in an amount of 1 to 5% by weight based on the total weight of the edible oil. If the content of the refining material is less than 1% by weight, the color saturation and specific odor are deteriorated. If the refining material content exceeds 5% by weight, the turbidity becomes high, and there is a fear of deposits.
이하, 본 발명을 실시예 및 제조예에 의해 상세히 설명한다. 단, 하기 실시예 및 제조예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 제조예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples and Production Examples. However, the following examples and preparations are merely illustrative of the present invention, and the content of the present invention is not limited by the following examples and production examples.
실시예 1. 칼라 오일의 제조Example 1. Preparation of color oil
라이코펜과 베타-카로틴을 함유하고 있는 파프리카, 토마토, 앵두, 고추, 오미자, 수박, 당근, 감, 오렌지, 귤, 금귤, 호박, 노란색 대추방울토마토, 피망, 풋고추, 미나리, 오이, 상추, 시금치, 브로콜리, 매실 등의 소재를 동결 건조한 후, 약 60mesh의 입도로 분쇄하였다. 상기 건조 분쇄한 소재를 30~60℃, 100~300bar에서 2시간 동안 초임계 이산화탄소 처리하여 라이코펜 또는 베타카로틴을 포함하는 정유물질을 추출하였으며, 보조용매로 95% 에탄올을 이용하였다. 상기 정유 물질을 식용유지와 혼합하고 교반하여 라이코펜과 베타카로틴을 고함유한 칼라 오일을 제조하였으며, 라이코펜과 베타카로틴의 비율을 조절하여, 칼라 오일의 채도를 조절함으로써, 빨간색, 주황색, 노란색, 초록색의 칼라 오일을 제조하였다. Lycopene and beta-carotene paprika, tomato, cherry, chili, omelet, watermelon, carrot, persimmon, orange, tangerine, kumquat, pumpkin, yellow jujube tomatoes, bell pepper, green pepper, cantaloupe, cucumber, lettuce, spinach, Broccoli, and plum were lyophilized and then ground to a particle size of about 60 mesh. The dried material was subjected to supercritical carbon dioxide treatment at 30 to 60 DEG C and 100 to 300 bar for 2 hours to extract an essential oil containing lycopene or beta carotene and 95% ethanol as an auxiliary solvent. The purified oil was mixed with edible oil and stirred to produce a finely colored oil shaking lycopene and beta carotene. The ratio of lycopene to beta carotene was adjusted to control the saturation of the color oil, so that red, orange, yellow, green Color oil was prepared.
보다 구체적으로는 빨간색의 칼라 오일을 제조하기 위하여, 식용유지인 대두유 100g에 파프리카, 토마토, 앵두, 고추, 오미자 및 수박으로 이루어진 군에서 선택된 어느 하나 이상의 소재로부터 추출한 정유물질 5g을 첨가하였다. More specifically, in order to prepare a red color oil, 5 g of an essential oil material extracted from at least one material selected from the group consisting of paprika, tomato, cherry, red pepper, omija and watermelon was added to 100 g of soybean oil as an oil for cooking.
또한, 주황색의 칼라 오일을 제조하기 위하여, 식용유지인 대두유 100g에 당근, 감 및 파프리카로 이루어진 군에서 선택된 어느 하나 이상의 소재로부터 추출한 정유물질 5g을 첨가하였다. Further, in order to prepare an orange color oil, 5 g of an essential oil material extracted from at least one material selected from the group consisting of carrot, persimmon and paprika was added to 100 g of soybean oil as an edible oil.
또한, 노란색의 칼라 오일을 제조하기 위하여, 식용유지 100g에 파프리카, 오렌지, 귤, 금귤, 호박 및 노란색 대추방울토마토로 이루어진 군에서 선택된 어느 하나 이상의 소재로부터 추출한 정유물질 5g을 첨가하였다.In addition, in order to prepare a yellow color oil, 5 g of an essential oil material extracted from at least one material selected from the group consisting of paprika, orange, mandarin orange, kumquat, amber and yellow jujubes was added to 100 g of edible oil.
또한, 초록색의 칼라 오일을 제조하기 위하여, 식용유지 100g에 파프리카, 피망, 풋고추, 미나리, 오이, 상추, 시금치, 브로콜리 및 매실로 이루어진 군에서 선택된 어느 하나 이상의 소재로부터 추출한 정유물질 5g을 첨가하였다.In addition, 5 g of purified oil material extracted from at least one material selected from the group consisting of paprika, bell pepper, green pepper, parsley, cucumber, lettuce, spinach, broccoli and plum was added to 100 g of edible oil to prepare a green color oil.
상기 과정을 통해 제조된 칼라 오일의 색상을 육안으로 관찰하였으며, 그 결과는 도 1에 나타내었다. The color of the color oil prepared through the above procedure was visually observed, and the results are shown in FIG.
실시예Example 2. Y-미로 실험(Y-maze test)을 통한 2. Through the Y-maze test 칼라color 오일의 인지능력 개선 효능 평가 Evaluating efficacy of improving cognitive ability of oil
2-1. 2-1. 실험 동물Experimental animal
실험동물공급업체(Samtako, Osan, Korea)로부터 4주령의 ICR-male mouse를 구입하여 7일간의 환경 적응 기간을 거치게 한 후, 모든 실험동물은 3마리씩 한 개의 사육케이스에 넣고 온도 22±2℃, 상대습도 50-55%, 조명 시간 12시간으로 동일한 실험실 환경에서 충분한 양의 식수와 사료를 공급하며 사육하였다. 실험동물들은 7일간의 적응기간이 종료된 후 control group과 trimethyltin chloride (TMT, Sigma-Aldrich Chemical Co., St. Louis, MO, USA) injection group(인지결함유발 대조군), sample group(들기름과 대두유 처리군)으로 분류하여 각 군마다 9마리씩 6군으로 나누어 4주간 실험하였다. Sample group은 21일 동안 각각 대두유, 들기름(2.5 mL/kg of bodyweight)을 매일 경구 투여하였고, 28일째 되는 날에 0.85% 식염수에 녹인 TMT (7.6 μg/kg of bodyweight)를 100 μL씩 마우스의 복강에 주사하여 인지결함을 유발시켰다. TMT injection 2일 후 Y-maze test 및 morris water maze test의 행동 실험을 6일간 진행하였다.Four-week-old ICR-male mice were purchased from an experimental animal supplier (Samtako, Osan, Korea) and allowed to undergo a 7-day adaptation period. All animals were placed in one breeding case, , Relative humidity of 50-55%, and illumination time of 12 hours in the same laboratory environment. Experimental animals were divided into control group and trimethyltin chloride (TMT, Sigma-Aldrich Chemical Co., St. Louis, MO, USA) injection group (cognitive defect-induced control group), sample group (perilla oil and soybean oil Treated group) and divided into 6 groups of 9 mice per each group for 4 weeks. The sample group was orally administered daily with soybean oil and perilla oil (2.5 mL / kg body weight) for 21 days, and 100 μL of TMT (7.6 μg / kg body weight) dissolved in 0.85% saline on the 28th day To induce cognitive defects. After 2 days of TMT injection, the behavioral tests of Y-maze test and morris water maze test were conducted for 6 days.
2-2. Y-미로 실험(Y-maze test)을 통한 2-2. Through the Y-maze test (Y-maze test) 칼라color 오일의 인지능력 개선 효과 확인 Identify the improvement of cognitive ability of oil
TMT injection 2일 후 Y-maze 실험을 실시하였다. 실험에 사용되는 Y-maze는 검은색 플라스틱 재질로 3개의 arm으로 구성되어 있고, 각 arm의 길이, 높이, 너비는 33, 15, 10 cm이다. 각 arm을 A, B, C로 정한 후 한쪽 arm에 마우스를 조심스럽게 놓고 8분 동안 마우스가 들어간 arm의 이동경로를 video-tracking system (Smart v3.0, Panlab SL, Barcelona, Spain)을 이용하여 기록하였다. 3개의 서로 다른 arm에 차례로 들어간 경우 1점(실제 변경, actual alternation)씩 부여하고, 변경 행동력(alternation behavior)은 총 통과횟수(total arm entry)와 점수를 이용하여 하기 수학식 1을 통해 계산하였다.Y-maze experiment was performed 2 days after TMT injection. The Y-maze used in the experiment is made of black plastic and consists of three arms. The length, height and width of each arm are 33, 15, and 10 cm. After setting each arm to A, B, C, carefully place the mouse on one of the arms and move the arm's movement for 8 minutes using video-tracking system (Smart v3.0, Panlab SL, Barcelona, Spain) . 1 point (actual change) is assigned to each of three different arms in turn, and the alternation behavior is calculated using the following equation (1) using the total arm entry and score .
*Maximum alternation=total number of arm entry-2* Maximum alternation = total number of arm entry-2
Y-maze test는 단기기억형태의 순간 공간인지력을 평가하기 위한 방법으로, 뇌의 해마부위에 비가역적인 손상을 일으킴으로써 AD와 유사한 증상을 나타내는 TMT를 이용하여 기억력과 학습능력이 감퇴된 마우스 모델을 대상으로 8분 동안 Y-maze에서의 마우스행동을 관찰한 결과는 도 2와 같다. TMT group은 control group (100%) 대비 약 79%로 기억력 저하(약 21% 감소)를 보였고, 대두유 group은 88%로 TMT group과 유의적인 차이가 없는 것으로 나타났다. 이에 반해 들기름 group은 TMT group과 비교하였을 때 기억력을 개선시킬 뿐만 아니라 control group과 유사한 것으로 나타났다. 도 3은 8분 동안 마우스들이 Y-maze의 각 arm을 통과한 총 횟수를 나타낸 것으로 마우스의 기본적인 운동능력에는 유의적 차이가 없는 것으로 나타났다. The Y-maze test is a method for evaluating the temporal spatial cognition of short-term memories. It uses a TMT that exhibits AD-like symptoms by causing irreversible damage to the hippocampus of the brain. The results of observing mouse behavior in Y-maze for 8 minutes are shown in Fig. The TMT group showed a decrease in memory (about 21%) compared to the control group (79%) and the soybean oil group (88%) showed no significant difference from the TMT group. In comparison with the TMT group, the perilla oil group was similar to the control group as well as improving memory. FIG. 3 shows the total number of times the mice passed through each arm of Y-maze for 8 minutes, and there was no significant difference in the basic athletic performance of the mice.
TMT에 중독된 실험동물은 자발성 간질, 공격성, 과민성 등 변연계 손상으로부터 나타나는 신경적 과잉행동을 나타내는데 도 2에서 TMT group은 control group과 비교하였을 때 같은 시간 당 arm 내에서의 이동거리가 현저하게 많았으며 대두유 group에서도 유사한 행동을 나타내었다. 반면에 들기름 group은 control group과 유의적인 차이가 없는 것으로 나타났다. 따라서 TMT 복강 주사로 유도된 인지결함 및 과잉행동 장애에 대한 들기름의 개선 효과를 나타내고 있다. TMT-induced laboratory animals exhibit neurogenic hyperactivity resulting from limbic damage such as spontaneous epilepsy, aggression, and hypersensitivity. In Figure 2, the TMT group has significantly greater travel within the arm per hour compared to the control group Soybean oil group showed similar behavior. On the other hand, the perilla oil group showed no significant difference from the control group. Therefore, it shows the improvement effect of perilla oil on cognitive deficit and hyperactivity disorder induced by TMT abdominal injection.
실시예Example 3. 모리스 수중 미로 실험(morris water maze test)을 통한 3. Through the Morris water maze test 칼라color 오일의 기억력 및 학습능력 개선 효과 확인 Confirming the improvement of memory and learning ability of oil
모리스 수중미로시험을 이용하면 공간학습 및 인지력 개선 여부를 측정할 수 있어, 치매의 예방 또는 치료용 약물을 탐색하는 한 방법으로 종종 이용된다. 실시예 2의 Y-maze 실험 종료 다음 날 실험동물의 공간기억 평가를 위해 morris water maze 실험을 실시하였다. 원형 수조(직경 150 cm, 높이 60 cm)안에 물을 30 cm 높이로 채우고(23±2℃), 수조 4분면의 한 구역에 escape platform을 설치하고 식용먹물(Cebesa, Valencia, Spain)을 풀었다. 실험 첫날은 수조에서 실험동물이 platform없이 60초간 자유롭게 수영하도록 하여 적응훈련을 시킨 후, 다음 날은 platform이 수면 위로 1 cm 보이게 하여 위치를 기억하도록 하였다(visible trial). 이후 4일 동안은 platform을 수면 아래로 2 cm로 보이지 않게 설정한 수조에서 매번 입수하는 위치(N, S, E, W zone)를 다르게 하고 하루 1번씩 반복하여 훈련시켰으며 video-tracking system (Panlab SL)을 이용하여 기록하였다(hidden trial). 실험동물이 60초안에 platform에 도달하는 경우에는 10초 동안 platform에 머물게 하였으며, platform을 찾지 못할 경우에는 손으로 위치를 안내해주어 platform에 위치하도록 하고 20초 동안 있도록 하였다. 실험 5일째에는 platform을 제거하고 working memory를 측정하기 위하여 60초 동안 platform이 있었던 구역(W zone)에 머무르는 시간(초)을 기록하는 probe test를 실시하였다.The Morris Underwater Labyrinth test can be used to measure spatial learning and cognitive enhancement, and is often used as a method to explore drugs for the prevention or treatment of dementia. The morris water maze experiment was performed the day after the Y-maze experiment of Example 2 to evaluate the spatial memory of the experimental animals. In a circular water tank (150 cm in diameter, 60 cm in height), the water was filled to a height of 30 cm (23 ± 2 ° C) and an escape platform was installed in a quadrant of the water tank and the edible inks (Cebesa, Valencia, Spain) . On the first day of the experiment, the experimental animals were allowed to swim freely for 60 seconds without a platform in the water tank, followed by adaptive training, and the next day, the platform remained visible by 1 cm above the water surface (visible trial). During the next 4 days, the platform was repeatedly trained once a day with different positions (N, S, E, W zone) obtained each time in a water tank set at 2 cm below the surface of the water. SL) (hidden trial). When the animal reached the platform in 60 seconds, it was allowed to stay on the platform for 10 seconds. If the animal could not be found, it was guided by the hand to position it on the platform for 20 seconds. On the fifth day of the experiment, a probe test was performed to record the time (in seconds) of staying in the zone (W zone) where the platform was located for 60 seconds to remove the platform and measure the working memory.
그 결과 Morris water maze 실험은 실험동물의 공간 기억 학습 능력을 평가하는 방법으로 결과는 도 3에 나타내었다. 실험기간(hidden trial)동안 대두유 group을 제외하고는 모두 시간의 경과와 더불어 platform을 찾아가는데 소요되는 시간(escape latency)이 감소하였다. TMT group은 control group과 비교하여 항상 platform (W zone)에 찾아가는 시간이 길었고, 들기름 group은 첫째 날에는 control group보다 찾아가는 시간이 길었으나, 4일째에 통계적으로 의미 있는 수준으로 감소한 것을 확인하였다. As a result, the Morris water maze experiment was performed to evaluate the spatial memory learning ability of the experimental animals. The results are shown in FIG. During the hidden trial, except for the soybean oil group, escape latency decreased with the passage of time. The TMT group had a longer time to visit the platform (W zone) than the control group, and the pericarp group had a longer time to visit than the control group on the first day, but decreased to a statistically significant level on the fourth day.
도 3은 5일째에 platform을 제거한 후 platform이 있었던 구간(W zone)을 지나가거나 머무르는 시간을 측정하여 공간기억력을 검사하는 probe test를 나타내며 결과는 다음과 같다. TMT group의 경우 24.5%로 control group의 31.5%과 비교하여 낮은 공간 기억력을 보였으며, 대두유 group (26.4%)은 TMT group과 유사한 공간기억력을 보였다. 반면 들기름 group (35.2%)은 원래 platform이 위치했던 구간에 대한 기억력이 상대적으로 우수했고, 또한 수조 4분면 중 platform이 위치한 특정 구역을 경유하는 횟수가 control group보다 유의적으로 많았거나 차이가 없는 것으로 나타나(p<0.05) TMT에 의한 공간 학습 및 기억력 손상이 개선된 것으로 나타났다.FIG. 3 shows a probe test for measuring spatial memory by measuring the time passed or staying in the zone (W zone) after platform was removed on the fifth day. The results are as follows. In the TMT group, 24.5% showed lower spatial memory than the control group (31.5%), and the soybean oil group (26.4%) showed spatial memory similar to the TMT group. On the other hand, the pericarp group (35.2%) had relatively good memory of the area where the platform was located, and the number of passages through the specific area where the platform was located was significantly larger ( P <0.05) showed that TMT improved spatial learning and memory impairment.
Umezawa 등에 의하면, α-linolenic acid/linoleic acid (ω-3/ω-6) 지방산 조성이 다른 해바라기씨 기름과 들기름을 노화를 촉진시켜 학습 및 기억력이 감퇴한 마우스(SAMP8)에게 공급한 결과 지방산의 α-linolenic acid 비율이 높은 들기름 투여군이 상대적으로 우수한 기억력, 학습력 및 행동장애 개선효과가 나타났다. 또한 노령 마우스를 이용한 동물 실험에서는 ω-3 지방산이 결핍된 식이군은 control군에 비하여 공간 인지 및 기억학습능력이 저하되었으며(14), 장기적인 ω-3 지방산 함유 식이는 저하된 기억력을 효과적으로 개선시키고 뇌의 지질과산화물 함량을 감소시켜 신경세포 사멸로 인한 퇴행성 장애가 발생하는 것을 예방하는 것으로 보고되었다(15). 대두유는 총 지방산의 85%가 불포화지방산이며 linoleic acid (65%), oleic acid (26%) 및 α-linolenic acid (9%)로 구성되어 있는 반면 들기름은 약 93%이 불포화지방산이 차지하며 α-linolenic acid (60%), oleic acid (17%), linoleic acid (16%)의 구성 차이를 보인다(4,16). 이에 따라 본 실험에서의 결과는 ω-3 지방산의 구성 함유량의 상대적 차이가 인지기능 개선에 일부 영향을 미친 것으로 판단된다. Umezawa et al. Reported that sunflower seed oil and perilla oil, which are different in α-linolenic acid / linoleic acid (ω-3 / ω-6) fatty acid composition, were fed to mice with reduced learning and memory capacity (SAMP8) Perilla oil, which had a high ratio of α-linolenic acid, showed relatively good memory, learning and behavioral impairment. In animal studies using old mice, omega-3 fatty acid-deficient diets reduced spatial cognition and memory learning ability compared to the control group (14). Long-term ω-3 fatty acid-containing diets effectively improved memory impairment It has been reported that reducing the lipid peroxide content of the brain prevents the degenerative disorder caused by neuronal cell death (15). Soybean oil is composed of 85% of total fatty acids, unsaturated fatty acids, linoleic acid (65%), oleic acid (26%) and α-linolenic acid (9% (16%), linoleic acid (60%), oleic acid (17%) and linoleic acid (16). Therefore, the results of this experiment suggest that the relative difference in the content of ω-3 fatty acids partially influences the improvement of cognitive function.
실시예Example 4. 아세틸콜린 4. Acetylcholine 에스터라제Estherazade (( AChEAChE ) 분비량 확인을 통한 ) Through confirmation of secretion amount 칼라color 오일의 신경 전달 능력 확인 Identification of neurotransmitter capacity of oil
Morris water maze test 종료 후 적출한 마우스 뇌 일정량에 10 volume의 lysis buffer를 넣고 Glass-Col homogenizer로 균질화한 후 12,000 rpm에서 30분간 원심분리 하였고, 그 상등액을 효소실험을 위하여 사용하였다. 모든 추출공정은 4℃에서 수행하였으며, Quant-iT™ protein assay kit (Invitrogen Co., Carlsbad, CA, USA)를 이용하여 추출한 효소액의 단백질함량을 측정하였다. 효소 5 μL에 50 mM sodium phosphate buffer 65 μL를 넣고 37℃에서 15분간 preincubation 시킨 후, 반응 혼합물에 250 mM substrate solution 70 μL를 첨가하고 10분간 incubation하고 microplate reader (Bio-rad, Hercules, CA, USA)로 405 nm에서 흡광도를 측정하였다. 마우스 뇌 조직 중의 AChE 활성은 control group 대비 % 활성으로 나타내었다. 그 결과는 도 5에 나타내었다. After the completion of the Morris water maze test, 10 volumes of lysis buffer was added to the extracted mouse brain, homogenized with a glass-col homogenizer, centrifuged at 12,000 rpm for 30 minutes, and the supernatant was used for enzyme experiments. All extraction procedures were performed at 4 ° C and the protein content of the extracted enzyme was measured using the Quant-iT ™ protein assay kit (Invitrogen Co., Carlsbad, Calif., USA). After adding 65 μL of 50 mM sodium phosphate buffer to the enzyme, preincubate at 37 ° C for 15 minutes, add 70 μL of 250 mM substrate solution to the reaction mixture, incubate for 10 minutes, and insert into a microplate reader (Bio-Rad, Hercules, CA, USA Absorbance at 405 nm. AChE activity in mouse brain tissue was expressed as% activity relative to control group. The results are shown in Fig.
Acetylcholine (ACh)의 합성과 분해에 관련된 효소로는 각각 choline acetyltransferase ( ChAT)와 acetylcholinesterase (AChE)가 있다. 따라서 뇌조직의 신경전달이 원활하게 이루어지려면 ACh 수준에 영향을 미치는 ChAT와 AChE 활성이 매우 중요하다. 다만 ACh분해효소로서의 AChE가 활성화되면 ACh의 농도가 줄어들어 뇌신경의 신호전달이 저하되어 인지능력이 떨어지므로 퇴행성 치매 환자의 치료에 있어 AChE 효소를 억제해 ACh의 농도를 증가시키는 방법이 이용되고 있다. TMT에 의한 뇌신경계 손상의 기본 기작 중 하나는 TMT가 muscarinic receptor 손상을 통한 콜린성 신경전달에서의 변화를 유도하여 손상을 유발하며, 이 손상은 특히 hippocampal neuron에서 발생되는 것으로 나타난다. 결국 TMT가 hippocampal region의 ACh의 농도를 감소시킨다는 것으로 미루어 볼 때 TMT와 AChE 활성 사이에 직접적인 상관관계는 알려지지 않았지만 mouse 뇌 조직에 존재하는 AChE의 활성을 증가시키는 것으로 판단된다. 따라서 Y-maze 및 morris water maze 실험 종료 후 마우스의 뇌를 적출하여 AChE activity를 측정하였다. TMT group은 control group (100%) 대비 약 148%로 AChE activity 활성이 증가하였으며, 들기름 group의 경우 103%로 TMT group 대비 30% 정도의 억제 효과를 보였다. 대두유 group은 약 140%로 AChE activity을 억제하나 들기름과 비교하였을 때 그 효과는 미비한 것으로 나타났다.Enzymes involved in the synthesis and degradation of acetylcholine (ACh) are choline acetyltransferase (ChAT) and acetylcholinesterase (AChE), respectively. Therefore, in order to facilitate neurotransmission of brain tissue, ChAT and AChE activity, which affect ACh levels, are very important. However, when AChE is activated as an ACh degrading enzyme, the concentration of ACh is decreased and the signal transmission of the brain is lowered, resulting in a decrease in cognitive ability. Therefore, a method of increasing the concentration of ACh by using AChE enzyme is being used in the treatment of degenerative dementia. One of the basic mechanisms of TMT-induced cranial nervous system damage is that TMT induces damage by inducing changes in cholinergic neuronal transmission through muscarinic receptor damage, which appears to occur in particular in the hippocampal neurons. As a result, TMT decreased the concentration of ACh in the hippocampal region. However, the direct correlation between TMT and AChE activity is not known, but it is considered to increase AChE activity in mouse brain tissue. Therefore, after the completion of the experiment of Y-maze and morris water maze, the brain of the mouse was extracted and the AChE activity was measured. TMT group showed AChE activity activity increased to 148% compared to control group (100%) and 103% in perilla oil group, showing 30% inhibition effect compared with TMT group. The soybean oil group inhibited AChE activity to about 140%, but the effect was insignificant when compared with perilla oil.
실시예Example 5. 5. 말론디알데히드Malondialdehyde (( MDAMDA ) 함량 변화를 통한 ) Through content change 칼라color 오일의 지질 과산화 억제 활성 확인 Identification of oil lipid peroxidation inhibitory activity
적출한 마우스 뇌의 일정량에 phosphate buffered saline을 넣고 추출하여 얻어낸 균질액 160 μL에 1% phosphoric acid 960 μL을 혼합한 후 0.67% thiobarbituric acid 320 μL를 넣고 95℃에서 1시간 동안 반응시켰다. 반응액은 원심분리기(Combi-514R, Hanil Co. Ltd., Seoul, Korea) 5,000 rpm에서 10분간 원심분리하고, 532 nm에서 상등액의 흡광도(Libra S32PC, Biochrom Ltd., Cambridge, UK)를 측정하였다. MDA 함량은 mg protein 당 nmole의 농도로 표시하였다. 그 결과는 도 4에 나타내었다. After adding phosphate buffered saline to the extracted mouse brain, 160 μL of the obtained homogenate was mixed with 960 μL of 1% phosphoric acid. Then, 320 μL of 0.67% thiobarbituric acid was added and reacted at 95 ° C. for 1 hour. The reaction solution was centrifuged at 5,000 rpm for 10 minutes in a centrifuge (Combi-514R, Hanil Co. Ltd., Seoul, Korea), and the absorbance of the supernatant (Libra S32PC, Biochrom Ltd., Cambridge, UK) was measured at 532 nm . The MDA content was expressed as the concentration of nmole per mg protein. The results are shown in Fig.
조직을 구성하는 세포에서의 과산화현상은 세포막 주요구성성분인 인지질을 구성하는 불포화지방산에 산소유리기와 결합하여 생기게 되며, 과산화지질은 세포막의 불포화지방산과 지단백질에서 유리기와 연쇄 반응하여 부산물로 malondialdehyde (MDA)를 생산한다. MDA는 산화적 스트레스 시 뇌조직의 각 영역에서 증가하는 것으로 알려져 있으며, 축적 시 DNA와 축합물을 형성하는 등 조직에 산화적 손상을 유발하는 것으로 보고되었다. 특히 뇌세포는 다른 장기에 비하여 불포화 지방산의 함량이 높아 산화적 손상을 받기 쉬우며, 뇌 신경세포에 산화적 스트레스를 가하게 되면 염증반응에 이은 신경독성을 일으켜 신경세포의 사멸이 촉진된다. 결국 이런 산화적 스트레스가 뇌 조직 내에서 지속되면 기억 손상 및 손실에 의한 장애를 일으킬 것으로 예상하고 있다. 이에 본 실험에서는 대두유와 들기름을 섭취한 마우스의 뇌 조직에 존재하는 지질과산화 중간생성물인 MDA의 함량을 비교해 보기위해 각 group의 MDA 함량을 측정하였다. Control group은 4.21 nmole/mg protein이었으며, TMT group은 이보다 증가한 5.45 nmole/mg protein로 나타났다. 대두유와 들기름 group의 MDA 함량은 각각 4.64, 3.20 nmole/mg protein으로 TMT group과 비교하였을 때 모두 MDA 생성을 억제하였으나 대두유는 유의적인 차이가 크지 못한 반면에 들기름은 TMT 대비 약 41%정도의 억제효과를 보였고 오히려 control보다 유의적으로 낮은 MDA 함량을 나타내었다. 들기름에는 항암성이 매우 강하다고 알려진 luteolin과 apigenin, caffeic acid, ascorbic acid, β-carotene, limonene, protocatechuic acid 등의 생리활성 물질이 함유되어 있다. 또한 우리나라에서는 들기름을 일반 식용유와 다르게 정제하지 않고 이용하기 때문에 이와 같은 생리활성 물질이 비교적 풍부하며 그로 인한 항산화 효과 등에 의해 mouse 뇌 조직 중의 지질 산화를 억제 할 수 있다고 보고되고 있다. 따라서 본 실험 결과에서 TMT는 뇌 특정부위의 신경세포를 손상하는 것으로 사료되며, TMT에 의해 유도되는 뇌 신경세포 손상에 대해 대두유 보다 들기름이 상대적으로 우수한 저해효과를 가지는 것으로 판단된다.The peroxidation phenomenon in the cells constituting the tissue is caused by binding to the free radicals of the unsaturated fatty acids constituting the main constituent phospholipid of the cell membrane and the lipid peroxidation is a by-product in the unsaturated fatty acids and lipoproteins of the cell membranes, resulting in a malondialdehyde (MDA ). MDA is known to be increased in various regions of brain tissue during oxidative stress and has been reported to cause oxidative damage to tissues such as DNA and condensation during accumulation. In particular, brain cells are more susceptible to oxidative damage due to higher content of unsaturated fatty acids compared to other organs. When oxidative stress is applied to brain nerve cells, they cause neurotoxicity after inflammatory reaction and promote nerve cell death. In the end, this oxidative stress is expected to cause memory impairment and loss due to persistence in brain tissue. In this experiment, MDA content of each group was measured in order to compare the content of MDA, a lipid peroxide intermediate present in brain tissue of mice fed soybean oil and perilla oil. The control group was 4.21 nmole / mg protein, and the TMT group showed an increase of 5.45 nmole / mg protein. MDA content of soybean oil and perilla oil groups were 4.64 and 3.20 nmole / mg protein, respectively, which inhibited MDA production compared to TMT group, but soybean oil did not show significant difference, while perilla oil had about 41% inhibitory effect And MDA content was significantly lower than control. The perilla oil contains physiologically active substances such as luteolin, apigenin, caffeic acid, ascorbic acid, β-carotene, limonene and protocatechuic acid, which are known to have very high anticancer properties. In Korea, it is reported that perilla oil is used without refining differently from common cooking oil. Therefore, it is reported that such physiologically active substances are relatively abundant and that lipid oxidation in mouse brain tissue can be inhibited by the antioxidant effect thereof. Therefore, TMT seems to damage neurons in specific areas of the brain, suggesting that TMT - induced damage to brain nerve cells is more effective than that of soybean oil.
실시예Example 6. 과산화물제거효소( 6. Peroxide Removal Enzyme ( superoxidesuperoxide dismutasedismutase ; SOD) 활성 변화를 통한 칼라 오일의 항산화 효과 확인; SOD) activity of color oil
적출한 마우스의 뇌를 10 volume의 lysis buffer를 넣고 Glass-Col homogenizer로 균질화한 후 12,000 rpm에서 30분간 원심분리 하여 상등액을 버리고 pellet을 취한다. 1X Cell Extraction Buffer (10X SOD Buffer 1 mL, 20% triton X-100 0.2 mL, 증류수 8.8 mL, 200 mM pMSF 10 ul)을 넣고 30분간 5분단위로 vortexing 해준 후, 1,000 rpm에서 10분간 원심분리 한 후 상등액을 실험에 이용하였다. 모든 공정은 4℃를 유지하였으며 추출한 상등액의 단백질함량을 측정하기 위하여 Quant-iT™ protein assay kit (Invitrogen Co)를 이용하였다. SOD 활성을 측정하기 위하여 SOD determination kit (Sigma-Aldrich Chemical Co.)를 사용하였으며 측정된 흡광도 값을 계산하여 SOD(U/mL)로 나타내었다. 그 결과는 도 5에 나타내었다.The brain of the extracted mouse is homogenized with 10 volumes of lysis buffer, and homogenized with a glass-col homogenizer. Centrifuge at 12,000 rpm for 30 minutes to discard the supernatant and take a pellet. 1X Cell Extraction Buffer (1 mL of 10X SOD Buffer, 0.2 mL of 20% triton X-100, 8.8 mL of distilled water, 10 μL of 200 mM pMSF) was vortexed for 30 minutes at 5 minutes and then centrifuged at 1,000 rpm for 10 minutes The supernatant was used for the experiment. All procedures were maintained at 4 ° C and the Quant-iT ™ protein assay kit (Invitrogen Co) was used to determine the protein content of the supernatant. SOD activity was measured by SOD determination kit (Sigma-Aldrich Chemical Co.). Absorbance was calculated and expressed as SOD (U / mL). The results are shown in Fig.
항산화 효소 중의 하나인 SOD는 세포에 유해한 환원 산소종을 과산화수소로 전환시키는 반응을 촉매로 하는 효소이며, SOD에 의해 생성된 H2O2는 peroxidase나 catalase에 의하여 무해한 물 분자와 산소분자로 전환시켜 산소 상해로부터 생체를 보호하는 기능으로 알려져 있다. 또한 SOD는 자유 라디칼을 근본적으로 제거하는 효소이고 다른 종류의 항산화제보다 우수한 효과를 나타내기 때문에 의약제제로서 많은 관심을 일으키고 있으며, 현재 항염증제재나 피부노화방지를 위한 미용제재로 화장품 등에 이용되고 있는 실정이다. 실험에 사용한 SOD assay kit-WST는 기존에 많이 이용되어왔던 xanthine oxidase의 inhibition을 통한 활성 측정법을 이용하면서도 highly water-soluble tetrazolium salt와 WST-1(2-(4-iodophenyl)-3-(4- nitrophenyl)-5-(2, -disulfi-phenyl)-2H-tetrazolium, monosodium salt)를 사용한다. WST-1은 superoxide anion과 반응하여 수용성의 formazan dye를 생성하는 한편 WST-1은 xanthine oxidase의 환원형과도 반응하지 않을 뿐 아니라 cytochrome C와 비교했을 때 superoxide anion과의 반응성이 70배나 낮아서 SOD의 농도가 낮은 샘플에서도 높은 감도를 보인다. 실험 결과 control group은 16.5 U/mg protein이었으며, TMT group은 이보다 감소한 11.7 U/mg protein로 나타났다. 대두유, 들기름 group의 SOD함량은 각각 12.6, 14.2 U/mg protein으로 대두유의 경우 TMT group과 차이가 거의 없지만 들기름 group의 경우 SOD의 감소를 효과적으로 억제하는 것으로 나타났다.One of the antioxidant enzymes, SOD, is an enzyme that catalyzes the conversion of reductive oxygen species that are harmful to cells into hydrogen peroxide. H 2 O 2 produced by SOD is converted into harmless water molecules and oxygen molecules by peroxidase or catalase It is known to protect the body from oxygen injury. In addition, SOD is an enzyme that essentially eliminates free radicals, and has been shown to be more effective than other antioxidants, resulting in a great deal of interest as a pharmaceutical preparation. Currently, SOD is used in cosmetics as an anti-inflammatory agent to be. The SOD assay kit-WST used in this study was composed of highly water-soluble tetrazolium salt and WST-1 (2- (4-iodophenyl) -3- (4- nitrophenyl) -5- (2, -disulfi-phenyl) -2H-tetrazolium, monosodium salt. WST-1 reacts with superoxide anion to produce water-soluble formazan dye, while WST-1 does not react with the reduced form of xanthine oxidase, and its reactivity with superoxide anion is 70 times lower than that of cytochrome C, High sensitivity is shown even in low concentration samples. The control group was 16.5 U / mg protein and the TMT group was 11.7 U / mg protein. The SOD contents of soybean oil and perilla oil groups were 12.6 and 14.2 U / mg protein, respectively. The soybean oil showed little difference from the TMT group, but the perilla oil group effectively inhibited the decrease of SOD.
실시예Example 6. 글루타티온( 6. Glutathione ( glutathineglutathine ; ; GSHGSH ) 함량 변화를 통한 ) Through content change 칼라color 오일의 Oil 산화적Oxidative 세포 손상 억제 효과 확인 Confirmation of cytotoxic effect
일정량의 마우스 뇌에 10 volume의 cold 5% metaphosphoric acid를 넣고 균질화한 후 15분간 원심분리(14,000 × g)하여 상등액을 얻어 실험에 사용하였으며, 2 M 4-vinylpyridine 10 μL를 더하여 oxidized glutathione 측정에 사용하였다. 모든 공정은 4℃를 유지하였으며 추출한 상등액의 단백질함량을 측정하기 위하여 Quant-iT™ protein assay kit (Invitrogen Co)을 이용하였다. Glutathione의 함량을 측정하기 위하여 glutathione (GSSG/GSH) detection kit (Enzo Diagnostics, Farmingdale, NY, USA)를 이용하여 측정하였으며, 측정된 total glutathione, 산화된 glutathione (oxidized glutathione)의 흡광도 값을 glutathione standard curve에 대입하여 oxidized GSH/total GSH (%)로 나타내었다. 그 결과는 도 5에 나타내었다.After the homogenization of 10 volumes of cold 5% metaphosphoric acid was added to a certain amount of mouse brain, the supernatant was obtained by centrifugation (14,000 × g) for 15 minutes and 10 μL of 2 M 4-vinylpyridine was added to measure oxidized glutathione Respectively. The whole process was maintained at 4 ° C and Quant-iT ™ protein assay kit (Invitrogen Co) was used to measure the protein content of the extracted supernatant. Glutathione content was measured using a glutathione (GSSG / GSH) detection kit (Enzo Diagnostics, Farmingdale, NY, USA) and the absorbance values of the measured total glutathione and oxidized glutathione (GSH) and total GSH (%). The results are shown in Fig.
뇌 조직의 glutathione은 산화적 세포손상에 대한 방어 작용을 나타내는 효소인 GSH- peroxidase와 GST의 기질로 사용되는 물질로 활성산소, 과산화지질 그리고 친전자성 물질들이 세포내에서 최종적으로 무독화되는 과정에 관여하며 세포내 지질과산화물질과 이물질의 제거, 아미노산 수송 및 저장, 간 해독 등 다양한 기능을 수행한다. 실험 결과 control group의 경우 총 glutathione에서 산화된 glutathione의 양이 8.4% 인 것에 비해 TMT group의 경우 10.4%를 나타내어 control group에 비해 산화된 glutathione의 비율이 증가된 것으로 나타났으며, 들기름 group은 5.3%로 glutathione의 산화 억제 효과가 뛰어난 것으로 나타났다. 그에 비해 대두유 group의 경우 14.6%로 TMT group 보다 산화된 glutathione의 비율이 증가 하는 것을 알 수 있었다. 산화적 스트레스에 지속적으로 노출된 rat에 vitamin A, E, C를 식이한 결과, vitamin E가 뇌 조직의 SOD, GSH 수치를 가장 많이 높인 것으로 나타났으며, 이를 고려할 때 본 실험에서의 결과는 들기름이 식용유를 포함한 다른 유지에 비해 상대적으로 vitamin E 등을 포함한 생리활성 구성 성분이 풍부하기 때문으로 판단된다.Glutathione in brain tissue is a substance used as a substrate of GSH-peroxidase and GST, which are enzymes that protect against oxidative cell damage. It is a process in which active oxygen, lipid peroxides and electrophilic substances are finally detoxified in cells And carries out various functions such as elimination of lipid peroxidation substances and foreign substances in cells, amino acid transport and storage, and liver decryption. In the control group, the amount of glutathione oxidized in total glutathione was 8.4%, that of TMT group was 10.4%, that of oxidized glutathione increased in the control group, 5.3% in the perilla oil group, Showed excellent antioxidant effect of glutathione. On the other hand, the ratio of oxidized glutathione was higher than that of TMT group in soybean oil group (14.6%). Vitamin A, E, and C were fed to rats exposed to oxidative stress. Vitamin E showed the highest levels of SOD and GSH in brain tissues. In conclusion, It is thought that this is due to the abundance of physiologically active components including vitamin E relative to other oils including edible oil.
실험의 결과는 평균과 표준편차(mean±SD)로 나타내었고, 실험군 간 차이의 통계적 유의성은 SAS version 9.1(SAS Institute Inc., Cary, NC, USA)를 이용하여 ANOVA 분산분석과 Duncan’s multiple range test로 유의성 검정을 시행하였다(p<0.05).The results were expressed as means and standard deviations (mean ± SD), and the statistical significance of differences between the experimental groups was analyzed using ANOVA variance analysis and Duncan's multiple range test (SAS Institute Inc., Cary, NC, USA) ( P <0.05). There was no significant difference between the two groups.
이하 본 발명의 칼라 오일을 유효성분으로 포함하는 인지기능 장애의 예방, 완화 또는 치료용 조성물의 제제예를 설명하나, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a preparation example of a composition for preventing, alleviating or treating cognitive dysfunction comprising the color oil of the present invention as an active ingredient will be described, but the present invention is not intended to be limited thereto but is specifically described.
제제예 1. 약학적 제제의 제조Formulation Example 1. Preparation of pharmaceutical preparations
1. 산제의 제조 1. Manufacturing of powder
칼라오일 20 mg
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above components are mixed and filled in airtight bags to prepare powders.
2. 정제의 제조2. Preparation of tablets
칼라오일 10 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
3. 캡슐제의 제조3. Preparation of capsules
칼라오일 10 mg
결정성 셀룰로오스 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
4. 주사제의 제조4. Preparation of injections
칼라오일 10 mg
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO42H2O 26 mgNa 2 HPO 4 2H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ml) 상기의 성분 함량으로 제조한다.(2 ml) per 1 ampoule in accordance with the usual injection preparation method.
5. 액제의 제조5. Manufacture of liquids
칼라오일 20 mg
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ml로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
제제예 2. 식품 제제의 제조Formulation Example 2. Preparation of food preparation
1. 건강식품의 제조1. Manufacture of health food
칼라오일 100 mg
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 g 70 g of vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 g 0.2 g of vitamin B12
비타민 C 10 mg
비오틴 10 g Biotin 10 g
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 g Folate 50 g
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
2. 건강음료의 제조2. Manufacture of health drinks
칼라오일 100 mg
비타민 C 15 gVitamin C 15 g
비타민 E(분말) 100 gVitamin E (powder) 100 g
젖산철 19.75 g19.75 g of ferrous lactate
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinic acid amide 3.5 g
비타민 A 0.2 gVitamin A 0.2 g
비타민 B1 0.25 gVitamin B1 0.25 g
비타민 B2 0.3gVitamin B2 0.3g
물 정량Water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the health beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
Claims (2)
A health functional food composition for preventing or alleviating cognitive dysfunction related diseases comprising color oil as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170029573A KR20180102868A (en) | 2017-03-08 | 2017-03-08 | Composition comprising Vegetable Oil for preventing, alleviating or treatment of congnitive dysfunction disorder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170029573A KR20180102868A (en) | 2017-03-08 | 2017-03-08 | Composition comprising Vegetable Oil for preventing, alleviating or treatment of congnitive dysfunction disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180102868A true KR20180102868A (en) | 2018-09-18 |
Family
ID=63718503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170029573A KR20180102868A (en) | 2017-03-08 | 2017-03-08 | Composition comprising Vegetable Oil for preventing, alleviating or treatment of congnitive dysfunction disorder |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20180102868A (en) |
-
2017
- 2017-03-08 KR KR1020170029573A patent/KR20180102868A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101262686B1 (en) | Composition for body fat reduction | |
KR101725150B1 (en) | Composition for improvement of learning and memory function comprising broccoli leaf extract or its fraction as effective component | |
JP2013241354A (en) | Phosphodiesterase 2 inhibitor | |
KR101694913B1 (en) | Composition for improvement of learning and memory function comprising onion extract or its fraction as effective component | |
KR20100015595A (en) | Novel use of hydroxytyrosol and olive extracts/concentrates containing it | |
JP7429739B2 (en) | A composition for preventing and/or improving brain dysfunction containing lutein or its salt and a processed product of a caltrops plant | |
EP2135616B1 (en) | Dried bilberries for influencing intestinal conditions | |
JP2006083151A (en) | Composition for preventing and ameliorating osteoporosis | |
JP6735224B2 (en) | Activator of glucose metabolism in astrocytes | |
US11110145B2 (en) | Composition for protecting cell from oxidative stress comprising green tea extract which has modified amounts of ingredients | |
KR101354370B1 (en) | A composition for improving ability of memory or concentration | |
KR20130097537A (en) | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory | |
US10799551B2 (en) | Composition for enhancing cognitive function comprising green tea extract which has modified amounts of ingredients | |
JP2015063507A (en) | Inhibitor for retinal disorder caused by aging | |
KR20180102868A (en) | Composition comprising Vegetable Oil for preventing, alleviating or treatment of congnitive dysfunction disorder | |
JP2019073476A (en) | Agent for atp production promotion | |
KR100510253B1 (en) | Functional Food Composition having Anti-oxidative, Anti-arthritic and Anti-dementia Activity | |
JP7281276B2 (en) | Cognitive function improver | |
KR100640094B1 (en) | Composition comprising the seed oil of Green Tea having Cholesterol-lowering or antioxidant activity | |
JP2012006905A (en) | Composition for skin care | |
US20210085742A1 (en) | Fruit extract and uses thereof | |
KR20190125804A (en) | Composition for Preventing or Treating Cognitive Dysfunction Comprising Extraction of Gentiana lutea or Compound Isolated therefrom | |
KR102463087B1 (en) | Fermented artemisia capillaris having anti-dementia and anti-oxidative activity, and manufacturing method thereof | |
KR20120090140A (en) | An food composition for enhancing memory containing extract of rubus coreanus miquel | |
IAHTISHAM-UL-HAQ et al. | HEALTH BENEFITS OF ANTHOCYANINS IN BLACK CARROT (Daucus carota) |